A5050960884- Botulinum Toxin and Related Neurological Disorders
- Stroke Rehabilitation and Recovery
- Cerebral Palsy and Movement Disorders
- Hereditary Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
- Balance, Gait, and Falls Prevention
- Lymphatic System and Diseases
- Long-Term Effects of COVID-19
- Intensive Care Unit Cognitive Disorders
- Pain Mechanisms and Treatments
- Neurological disorders and treatments
- Body Contouring and Surgery
- COVID-19 and Mental Health
- Muscle and Compartmental Disorders
- Psychosomatic Disorders and Their Treatments
- Ophthalmology and Eye Disorders
- Acute Ischemic Stroke Management
- Sympathectomy and Hyperhidrosis Treatments
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2021-2025
Azienda Ospedaliero Universitaria Maggiore della Carita
2021-2025
Ospedale Maggiore
2021-2024
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2021-2024
Magna Graecia University
2023-2024
<h3>Importance</h3> Although plenty of data exist regarding clinical manifestations, course, case fatality rate, and risk factors associated with mortality in severe coronavirus disease 2019 (COVID-19), long-term respiratory functional sequelae survivors COVID-19 are unknown. <h3>Objective</h3> To evaluate the prevalence lung function anomalies, exercise impairment, psychological among patients hospitalized for COVID-19, 4 months after discharge. <h3>Design, Setting, Participants</h3> This...
Abstract Many coronavirus disease 2019 (Covid-19) survivors show symptoms months after acute illness. The aim of this work is to describe the clinical evolution Covid-19, one year discharge. We performed a prospective cohort study on 238 patients previously hospitalized for Covid-19 pneumonia in 2020 who already underwent follow-up 4 post-Covid-19. 200 consented participate 12-months assessment, including: pulmonary function tests with diffusing lung capacity carbon monoxide (DLCO);...
Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement quality life (QoL). Current evidence its efficacy based mainly post stroke spasticity. This study aims to clarify role BoNT-A in context non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, traumatic brain injury clinical indication perform treatment. Subjects were evaluated before injection after 1,...
Background/Objectives: Breast cancer-related lymphedema (BCRL) is a significant complication of breast cancer (BC) treatment, characterized by swelling and fluid accumulation. Many risk factors have already been proven to be related BCRL; meanwhile, many others are still debated poorly investigated in the literature. This study potential involvement commonly prescribed chronic medications BCRL development. Methods: observational retrospective cohort included 162 post-surgical survivors...
The goal-setting process is pivotal in managing patients with disabling spasticity. This case–control study assessed the role of diagnostic nerve blocks guiding within goal-targeted treatment spasticity botulinum neurotoxin-A. In this study, underwent either a based on patient’s needs and clinical evaluation (control group) or additional block procedures (case group). All enrolled focal neurotoxin-A injection 1-month follow-up during which goal achievement was quantified using attainment...
BACKGROUND: Around 40% of stroke survivor develop spasticity. Plantar flexors (PF) muscles are often affected, with severe functional impairment. The treatment choice is botulinum toxin type A (BoNT-A) combined adjuvant treatments. temporary pharmacological effect implies periodic reassessment and reinjection. These long-term chronic programs require monitoring the impact each cycle clinical evolution in relation to aging repeated interventions.AIM: Evaluating changes level patients...
One of the aims diagnostic nerve blocks is to identify overactive muscles that lead a specific spasticity pattern. However, date, there no evidence on how may affect botulinum neurotoxin-A (BoNT-A) dose in patients with spasticity. This case-control study assess role block defining BoNT-A starting at first treatment. Patients upper and lower limb treated for time were retrospectively divided into two groups: Group 1 (n = 43) was evaluated clinical assessment block; 2 56) underwent only....
Objective: To compare the effect of rectus femoris diagnostic motor nerve blocks (DNB) with anaesthetics and muscle botulinum toxin (BoNT-A) injection in multiple sclerosis patients unilateral stiff-knee gait. Design: Prospective observational study Subjects/Patients: Multiple stable condition. Methods: Patients underwent evaluation before 1 hour after anaesthetic block, month injection. Assessment included a 10-m walking test, 6-minute timed-up-and-go (TUG) Baseline Expanded Disability...
Equinovarus foot is one of the most commonly spasticity related conditions in stroke survivors, leading to an impaired gait and poor functional performances. Notably, spastic muscles undergo a dynamic evolution following typical pathophysiological patterns. Botulinum Neurotoxin Type A (BoNT-A) gold standard for focal treatment, ultrasound (US) imaging widely recommended guide injections monitor muscle evolution. The role BoNT-A influencing fibroadipose degeneration still unclear. In this...
The present study aimed to evaluate the reasons and determinants of BoNT-A discontinuation in patients with stroke, multiple sclerosis, spinal cord injury, traumatic brain injury.It is a retrospective 56 discontinuer treated botulinum toxin between January 2011 December 2021. Discontinuation rates their predictors were estimated using Kaplan-Meier, Log rank test, Cox's regression method analyses.The mean age was 56.54 years, 53.57% affected by post-stroke spasticity, 17.86% 12.5% 16.07%...
Axillary web syndrome (AWS) is a highly prevalent surgical complication affecting BC survivors. It presents as subcutaneous cording that limits the upper limb range of motion (ROM) and causes pain. Its etiology still debated, its treatment not well defined. Therefore, we aimed to investigate safety, tolerability efficacy our specific AWS rehabilitative protocol. We conducted an observational retrospective study on cohort 92 patients referred oncological outpatient service university...
Botulinum Neurotoxin type-A (BoNT-A) is the treatment of choice for focal post-stroke spasticity (PSS). Due to its mechanism action and administration method, some authors raised concern about possible systemic diffusion leading contralateral muscle weakness autonomic nervous system (ANS) alterations. Stroke itself a cause motor disability ANS impairment; therefore, it mandatory prevent any source additional loss strength adjunctive disturbance. We enrolled 15 hemiparetic stroke survivors...